InVision® platform
Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients
InVisionFirst®Lung
Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients
Radar™
A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform
Our Mission
We are transforming the lives of cancer patients and their families through the power of liquid biopsy
Latest News and Events
Inivata Announces Clinical Collaboration with Princess Margaret Cancer Center for the use of its Liquid Biopsy Assays
Inivata, a leader in liquid biopsy, today announced a clinical collaboration with the Princess Margaret Cancer Center in Toronto, Canada, for the use of Inivata’s liquid biopsy assays, InVisionFirst®-Lung and RaDaR™ in two separate studies. Read More
Personalised circulating cell-free tumour DNA analysis for detection of minimal residual disease and recurrence in patients with head and neck squamous cell carcinoma
Susanne Flach, Karen Howarth, Sophie Hackinger, Christodoulos Pipinikas, Pete Ellis, Kirsten McLay, Giovanni Marsico, Christoph Walz, ... Read More
Changing Lives
Patients are at the heart of everything we do.
Our first product is for advanced Non-Small Cell lung Cancer and our world-leading tests are already impacting patients’ lives.
This is the story of the first patient Inivata tested.
